Key result
Triple-site cardiac resynchronization in a patient with end-stage heart failure supported by an intra-aortic balloon pump resulted in functional improvement and 17-month survival.
Why the study?
Does implantation of a triple-site cardiac resynchronization system improve clinical status and survival in a patient with end-stage heart failure supported with an intra-aortic balloon pump?
Case Report (n=1)
No
Does implantation of a triple-site cardiac resynchronization system improve clinical status and survival in a patient with end-stage heart failure supported with an intra-aortic balloon pump?
Triple-site cardiac resynchronization may provide significant clinical improvement and prolong survival in select patients with end-stage heart failure dependent on an intra-aortic balloon pump.
Hypothesis-generating for triple-site CRT in IABP-supported end-stage HF; should not yet change practice.
The authors present the case of a 62-year-old male patient with an implantable cardioverter-defibrillator and end-stage heart failure supported with an intra-aortic balloon pump. Implantation of a triple-site cardiac resynchronization system and complex heart failure treatment brought a significant improvement, return to home activity and 17-month survival. The patient died due to heart failure aggravation. Within this time he was rehospitalized and successfully treated twice for an electrical storm.
No takes yet. Share an insight, caveat, or question.
Ciszewski et al. (2014) conducted a case report in End-stage heart failure (n=1). Triple-site cardiac resynchronization (TriV) was evaluated on Survival and functional status. Triple-site cardiac resynchronization in a patient with end-stage heart failure supported by an intra-aortic balloon pump resulted in functional improvement and 17-month survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: